Performance status -2 - Symptomatic, 50 in bed Posts on Medivizor
Navigation Menu

Performance status -2 – Symptomatic, 50 in bed Posts on Medivizor

Searching for participants with high risk relapsed or unresponsive Hodgkin lymphoma to try a treatment combination.

Posted by on Jul 29, 2019 in Hodgkin's lymphoma | 0 comments

In a nutshell This study will investigate the effects of nivolumab (Opdivo) and brentuximab vedotin (Adcetris) after stem cell transplant in patients with high risk relapsed or refractory Hodgkin lymphoma (RRHL). The main outcome that will be measured is progression-free survival. This trial is recruiting in multiple locations in the United States. The...

Read More

Searching for patients with recurrent or non-responsive lymphoma to try this new treatment option

Posted by on Jun 29, 2019 in Hodgkin's lymphoma | 0 comments

In a nutshell This phase 1 study is evaluating the safety and effectiveness of a new T-cell therapy combined with nivolumab (Opdivo) for patients with lymphoma that has come back or stopped responding to treatment. The main outcome to be measured will be the number of patients who have side effects. This study is recruiting in Washington, D.C. and Salt...

Read More

Searching for patients with untreated small lymphocytic lymphoma to test combined immunotherapy

Posted by on Jun 29, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This phase 2 study is evaluating the effectiveness of a new combination therapy for small lymphocytic lymphoma (SLL). The main outcome to be measured will be the number of patients who have a complete disappearance of all signs of cancer. This study is recruiting in Rochester, New York, US. The details Typical treatments for SLL include...

Read More

Searching for patients with untreated chronic lymphocytic leukemia to test combined immunotherapy

Posted by on Jun 29, 2019 in Leukemia | 0 comments

In a nutshell This phase 2 study is evaluating the effectiveness of a new combination therapy for chronic lymphocytic leukemia (CLL). The main outcome to be measured will be the number of patients who have a complete disappearance of all signs of cancer. This study is recruiting in Rochester, New York, US. The details Typical treatments for CLL...

Read More

Looking for young patients with non-Hodgkin’s lymphoma to test a treatment combination

Posted by on Jun 14, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This phase 3 trial is comparing the effectiveness of ibrutinib (Imbruvica) plus chemotherapy versus chemotherapy alone in children and young adults with B-cell non-Hodgkin’s lymphoma (NHL). The main outcome to be measured will be survival without cancer returning, growing or spreading. The details Ibrutinib is a targeted therapy...

Read More

Searching for patients with previously untreated DLBCL to try this new treatment combination

Posted by on Mar 15, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study is comparing the effectiveness of R-CHOP chemotherapy with or without enzastaurin (Kinenza) in patients with previously untreated diffuse large B-cell lymphoma (DLBCL). The main outcome to be measured will be overall survival at the end of the study. The details The current standard first-line treatment for DLBCL is R-CHOP...

Read More

Searching for patients to test a combination of targeted therapies for chronic lymphocytic leukemia

Posted by on Mar 9, 2019 in Leukemia | 0 comments

In a nutshell This trial is examining the effectiveness of ibrutinib (Imbruvica) and obinutuzumab (Gazyva) with or without venetoclax (Venclexta) in the treatment of chronic lymphocytic leukemia (CLL). The main outcome to be measured will be survival without cancer growing or spreading. This trial is recruiting in various places around the...

Read More

Searching for patients with chronic lymphocytic leukemia to test zanubrutinib compared to ibrutinib

Posted by on Jan 27, 2019 in Leukemia | 0 comments

In a nutshell This trial is looking at the effectiveness of zanubrutinib compared to ibrutinib in the treatment of patients with unresponsive or relapsed chronic lymphocytic leukemia (CLL). The main outcome to be measured will be overall response rate. The study will be carried out in the United States.  The details Chronic...

Read More

Searching for patients to test venetoclax with azacitidine treatment for acute myeloid leukemia

Posted by on Jan 27, 2019 in Leukemia | 0 comments

In a nutshell This trial is comparing the safety and effectiveness of venetoclax (Venclexta) and azacitidine (Vidaza) with azacitidine alone in patients with acute myeloid leukemia (AML). The main outcome to be measured will be overall survival. Complete remission (no signs of cancer after treatment) will also be measured. The details Acute...

Read More

Ibrutinib in combination with bendamustine and rituximab improves quality of life factors in patients with severe impairment

Posted by on Feb 24, 2018 in Leukemia | 0 comments

In a nutshell This study examined how treatment with ibrutinib (Imbruvica), rituximab (Rituxan), and bendamustine (Treanda) impacts quality of life in chronic lymphocytic leukemia (CLL) patients. Factors such as fatigue, physical functioning, and well-being were all improved among those patients with the lowest scores before treatment. Some background...

Read More

Looking for patients with untreated chronic lymphocytic leukemia to test an ibrutinib and fludarabine treatment

Posted by on Sep 11, 2017 in Leukemia | 0 comments

In a nutshell This phase 2 clinical trial will test the safety and effectiveness of an ibrutinib (Imbruvica) and fludarabine (Fludara) treatment in patients with previously untreated chronic lymphocytic leukemia (CLL). The primary outcome will be measured by the safety and effectiveness of the treatment. The details Ibrutinib is a drug that...

Read More

Looking for patients with untreated mantle cell lymphoma to test the effectiveness of a combination therapy including acalabrutinib

Posted by on Aug 21, 2017 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This phase 3 clinical trial will test the effectiveness of acalabrutinib (ACP-196) with rituximab (Rituxan) and bendamustine (Treanda) in treating patients with previously untreated mantle cell lymphoma. The primary outcome will be measured by the time until the disease progresses. The details Acalabrutinib is an investigational...

Read More